Adia Med Inc ADIA
Set alert
0.12 USD 0.00 0.00%
At close · Oct 30
0.12 Day range 0.12
0.025 52-week range 0.278
- YTD
- +53.85%
- 1 year
- +200.00%
- Open
- 0.12
- Prev close
- 0.12
- Mkt cap
- 11.33M
- Vol
- 15.57K
- Avg vol
- 13.24K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.12
- High
- 0.12
1M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
News
- Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues
- Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash
- Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position
- Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million
- Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line
- Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products
- Nasdaq Shareholder Requirements Just Verified By Adia Med
- From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team
- Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting
- Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Your note
Sign in to keep a note on ADIA — it syncs with the Stock Master app.